Loading
Life sciences · Review
Clinical Microbiology Reviews · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
SUMMARY Campylobacter species, particularly Campylobacter jejuni and Campylobacter coli, are leading causes of bacterial gastroenteritis worldwide, responsible for an estimated 500 million cases of acute diarrheal illness annually. Despite their global prevalence and association with severe post-infectious sequelae such as Guillain-Barré syndrome, no licensed vaccine exists, and the growing threat of antimicrobial resistance further complicates clinical management. This review synthesizes current knowledge on the epidemiology, genomic diversity, antimicrobial resistance mechanisms, and vaccine development strategies for Campylobacter species, with emphasis on global trends and public health relevance in the United States. Through a One Health lens, we examine transmission across human, animal, and environmental reservoirs, and highlight the role of integrated genomic surveillance in tracking clonal expansion, horizontal gene transfer, and resistance dissemination. We also examine historical and current approaches to vaccine development, including whole-cell, subunit, glycoconjugate, and genomics-guided antigen discovery strategies. Challenges such as antigenic variability, phase variation, and inadequate experimental models have impeded progress, though recent genomics-informed interventions show promise in both poultry and human contexts. Continued investment in genomic surveillance, antimicrobial resistance, and rational antigen selection will be essential for developing effective vaccines and reducing the global burden of campylobacteriosis.